GE HealthCare Acquired SOFIE Biosciences for $945 Million

The acquisition grants GE HealthCare access to a domestic supply chain of PET radiopharmaceutical manufacturing sites.

Updated on Oct. 5, 2026 in Healthcare

Isometric editorial illustration of a stainless steel medical isotope container in a cleanroom, symbolizing pharmaceutical supply chain infrastructure. — GE HealthCare has agreed to acquire SOFIE Biosciences for $945 million, expanding its network of PET radiopharmaceutical manufacturing facilities across the United States. AI Illustration. Upload story photo >

Live Poll

Does company consolidation in the medical industry generally lead to better patient access to care?

GE HealthCare has reached a definitive agreement to purchase SOFIE Biosciences from Trilantic North America for $945 million in cash. The deal incorporates a network of U.S. manufacturing facilities into the buyer's existing diagnostic business.

Why it matters

The move enables GE HealthCare to capture more value from the high-growth radiopharmaceutical market by controlling the domestic supply chain for short-lived medical isotopes. This integration aims to bolster its position in advanced diagnostic imaging infrastructure.

GE HealthCare is acquiring 15 contract manufacturing organization sites and 21 cyclotrons for $945 million. This follows a 2025 performance where the company's imaging agents supported 140 million procedures.

The players

GE HealthCare

A global medical technology firm that provides imaging, ultrasound, and diagnostic agents to healthcare providers.

SOFIE Biosciences

A developer and manufacturer of PET radiopharmaceuticals that operates a network of cyclotrons and contract manufacturing sites.

Trilantic North America

A private equity firm that currently owns SOFIE Biosciences.

The details

GE HealthCare will integrate SOFIE Biosciences into its Pharmaceutical Diagnostics segment to support the distribution of time-sensitive PET radiopharmaceuticals. By adding 15 manufacturing sites to its operational footprint, the company gains significant domestic capacity for production and logistics. The transaction is structured as a cash purchase and remains subject to standard regulatory approvals before the deal can close.

October 5, 2026: GE HealthCare announced the acquisition agreement.
First half of 2027: The expected closing date for the transaction.

Market Landscape

The acquisition follows a trend of vertical integration aimed at solving the logistical constraints inherent in managing short-lived isotope supply chains. It marks a shift as diagnostic companies move to internalize the complex cold-chain logistics required to meet the FDA’s oversight of radiopharmaceutical manufacturing standards.

Operators in the diagnostic space should monitor how this consolidation affects regional access to PET radiopharmaceuticals and potential shifts in contract manufacturing pricing. Review supplier service level agreements now to prepare for potential changes in the domestic supply network by mid-2027.

The takeaway

Large-scale acquisitions in the diagnostic sector signal a shift toward controlling the physical supply chain for highly perishable medical goods. Owners should track this integration to see if it creates a benchmark for regional logistics speed and reliability.